

Supplemental Approvals

Generic Name (Trade Name—Company)

November 27, 2018

Eltrombopag

(Promacta—Novartis)

Combined with standard immunosuppressive therapy, drug targets treatment-resistant SAA

Uses/Notes

[Novartis announced](#) that FDA has expanded the approval of eltrombopag for first-line treatment of adults and pediatric patients aged 2 years and older with severe aplastic anemia (SAA) when the drug is taken in combination with standard immunosuppressive therapy.

SAA is a rare, life-threatening, acquired blood disorder in which a patient's bone marrow fails to produce enough red blood cells, white blood cells, and platelets. As a result, people living with this serious disease may experience debilitating symptoms and complications, such as fatigue, trouble breathing, recurring infections, and abnormal bruising or bleeding that can limit their daily activities.

Eltrombopag is an oral thrombopoietin receptor agonist that is already approved for SAA in patients who have had an insufficient response to IST. It is also approved for adults and children with chronic immune thrombocytopenia (ITP) who are refractory to other treatments, and for the treatment of thrombocytopenia in patients with chronic hepatitis C virus (HCV) infection.

In the clinical study upon which approval was based, the most common adverse reactions reported (incidence ≥5%) were abnormal liver function tests, rash, and skin discoloration, including hyperpigmentation.

Source URL:

<http://aphanet.org/supplemental-approvals/combined-standard-immunosuppressive-therapy-drug-targets-treatment-resistant>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.